Search Results - "V. I. Mogilnaya"

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) by Litvinenko, I. V., Odinak, M. M., Mogil’naya, V. I., Emelin, A. Yu

“…An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a…”
Get full text

Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia by Litvinenko, I. V., Odinak, M. M., Mogil’naya, V. I., Perstnev, S. V.

“…This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in…”
Get full text

Hyperhomocysteinemia in Parkinson’s disease – new variant of complications of ongoing therapy or specific biochemical marker of the disease? by I. V. Litvinenko, M. M. Odinak, O. S. Sologub, V. I. Mogilnaya, V. M. Schmeleva, A. A. Saharovskaya

“…Homocysteine is an amino acid with excitotoxic effect on the nervous system, and its elevated level is an independent risk factor for cerebrovascular disease…”
Get full text

Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole by Letvinenko, I V, Odinak, M M, Mogil'naia, V I

“…An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3…”
Get more information

Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial) by Litvinenko, I V, Odinak, M M, Mogil'naia, V I, Emelin, A Iu

“…Forty-one Parkinson's disease patients with dementia (21 galantamine group, 20--control group) with onset of dementia at least two years after the…”
Get more information